Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.54 |
| ▸ | BID | P55957 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | BCL2 | P10415 | 13/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.49 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067449 | 1.00 | BCL2A1 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL19867786 | 0.91 | BCL2 (0.50) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL20082257 | 0.90 | BCL2A1 (0.51) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL18214247 | 0.89 | BCL2A1 (0.50) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL19774754 | 0.88 | BCL2A1 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL19692632 | 0.86 | BCL2 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL25243081 | 0.85 | BCL2 (0.48) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL31321339 | 0.84 | BCL2 (0.55) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL24775466 | 0.84 | BCL2 (0.55) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL28839728 | 0.84 | BCL2 (0.51) | BCL2A1BIDMCL1BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2A1 2/4885BID 17/4885MCL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.